CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • About
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Top Biotech Industry Trends to Watch for in 2022

Top Biotech Industry Trends to Watch...

Encore Healthcare's VP of Clinical Operations Carrie Hylton-Proffitt, RRT Earns Accreditation with ACHC

Encore Healthcare's VP of Clinical...

Challenges Facing Biotech Companies Seeking Funding

Challenges Facing Biotech Companies...

How are Advancements in Biotechnology Help People Improve their Lives?

How are Advancements in Biotechnology...

Key Trends in Bioengineering to Watch for in 2022

Key Trends in Bioengineering to Watch...

How AI is Reshaping the Biotechnology Sector

How AI is Reshaping the Biotechnology...

Dr. Soren Thestrup-Nielsen M.D Joins Mainz Biomed's Strategic Advisory Board

Dr. Soren Thestrup-Nielsen M.D Joins...

Gene Mack Positioned as the Chief Financial Officer at Imcyse

Gene Mack Positioned as the Chief...

Top Biotech Industry Trends to Watch for in 2022

Top Biotech Industry Trends to Watch...

Encore Healthcare's VP of Clinical Operations Carrie Hylton-Proffitt, RRT Earns Accreditation with ACHC

Encore Healthcare's VP of Clinical...

Challenges Facing Biotech Companies Seeking Funding

Challenges Facing Biotech Companies...

How are Advancements in Biotechnology Help People Improve their Lives?

How are Advancements in Biotechnology...

Key Trends in Bioengineering to Watch for in 2022

Key Trends in Bioengineering to Watch...

How AI is Reshaping the Biotechnology Sector

How AI is Reshaping the Biotechnology...

Dr. Soren Thestrup-Nielsen M.D Joins Mainz Biomed's Strategic Advisory Board

Dr. Soren Thestrup-Nielsen M.D Joins...

Gene Mack Positioned as the Chief Financial Officer at Imcyse

Gene Mack Positioned as the Chief...

Sporos Bioventures Raises $38.1 Million in Series A Financing

Life Sciences Review Life Sciences Review | Monday, May 17, 2021
Tweet

Sporos Bioventures made its launch official with the close of a $38.1 million Series A financing.


FREMONT, CA: Sporos Bioventures, LLC (the Company or Sporos) made its launch official with the close of a $38.1 million Series A financing. The organization was formed by a group of biotech executives, entrepreneurs, academic scholars, and investors to catalyze the fast and effective development of innovative therapies targeting unique disease mechanisms in cancer and immune diseases. Sporos seeks to bring new hope to patients in a more effective and impactful manner by leveraging its extensive array of industry leaders, strategic resources, and operational expertise. In addition to Series A, Michael Wyzga, M.B.A., former Genzyme CFO, joins the team as Founding CFO.


"Sporos was founded to accelerate the development of new medicines by addressing inefficiencies and risk in the establishment of new biotech companies," said Peter Feinberg, Sporos co-founder and member of the board of directors. "By leveraging our extensive network, including the Texas Medical Center, which is the world's largest research and medical ecosystem, we first identify transformative scientific opportunities and then deploy our top-tier talent, funding and operational support to drive these insights into a growing pipeline of first-in-class treatment options."


Sporos begins with four entities, each based on truly novel mechanisms governing cancer and immune disease. The organization intends to use the Series A proceeds to support the development of lead assets across the Sporos portfolio and expand the Sporos team.


Tvardi, Sporos' most advanced company, is working on small molecule inhibitors of STAT3, a major regulatory protein involved in cancer cell survival and immune evasion, and the pathogenesis of several inflammatory and fibrotic diseases. TTI-101, Tvardis' lead asset in cancer, has been shown in initial clinical studies to be well accepted and to have clinical activity across a wide range of tumours, such as multiple durable responses.


"By strategically deploying valuable resources to young companies that would not typically be supported by top-tier seasoned talent and infrastructure, we believe that we can efficiently bring a diverse set of therapies through clinical development," said Mr Wyzga. "I am thrilled to join a team with decades of scientific and operational expertise and look forward to guiding our strategic and financial growth."


Weekly Brief

loading
Top 10 Biotech Startups Companies - 2022
> <
  • DNA Sequencing 2022

    Top Vendors

    Current Issue
  • BioTech Startups 2022

    Top Vendors

    Current Issue
  • DNA Sequencing 2022

    Top Vendors

    Current Issue
  • BioTech Startups 2022

    Top Vendors

    Current Issue

Read Also

Role of Predictive Genomics in Sustainable Healthcare

Role of Predictive Genomics in Sustainable Healthcare

A Conversational AI Approach to Regulatory Intelligence

A Conversational AI Approach to Regulatory Intelligence

A rise in DNA Sequencing Market is expected in coming years

A rise in DNA Sequencing Market is expected in coming years

Omniabio Inc. Announces Private Investor

Omniabio Inc. Announces Private Investor
Data analysis for next-generation sequencing worth USD1.2 billion by 2026 - Cloud-based platforms emerging as preferred solutions

Data analysis for next-generation sequencing worth USD1.2 billion by 2026 - Cloud-based platforms emerging as preferred solutions

Lithuania's Vision to Become a Biotech Hub in Europe

Lithuania's Vision to Become a Biotech Hub in Europe

Bridging the Diversity Gap in Genomics

Bridging the Diversity Gap in Genomics

How does Biotechnology Provide Solutions to Human Needs?

How does Biotechnology Provide Solutions to Human Needs?
Loading...

Copyright © 2022 Life Science Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/sporos-bioventures-raises-381-million-in-series-a-financing--nwid-361.html